GUSKA
- Biotech or pharma, therapeutic R&D
Guska (https://guska.bio/) is developing innovative oncolytic virus-based cancer therapies to improve the quality of life for patients suffering from some of the most devastating forms of cancer.
Our technology is based on a proprietary Platform, in which we engineer RNA viruses using AI and synthetic biology to enhance tumor specificity. We developed a Unique and Safe technology with genetic attenuation distributed throughout all the viral the genome preventing reversion to virulence.
To further boost tumor targeting and enable systemic delivery, we are developing proprietary technology to encapsulate our viruses in NLPs (nano lipid particles) cover with anti-pan-carcinoma antibodies. This dual approach (precision viral engineering + targeted delivery) gives us a strong edge in safety, efficacy, and differentiation from existing oncolytic therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}